Compare Smith & Nephew plc (SNN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.89 (market cap $21.89B). The key difference: Consumer Discretionary Select Sector SPDR Fund is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| SNN | XLY | |
|---|---|---|
Market Cap | $11.10B | $21.89B |
Volume | 1,051,703 | 5,690,342 |
Sector | Health | — |
52-Week High | $37.17 | $124.52 |
52-Week Low | $26.42 | $105.64 |
Typical Hold Time | 121 Days | 114 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
XLY trades at $112.72, up 1.22% today, with a bullish technical signal despite mixed moving average and oscillator readings. The ETF shows strong analyst support with a 100% buy rating from coverage, though recent underperformance versus consumer staples highlights sector rotation pressures. Key technical levels show support at $110-$111 and resistance at $112-$113, with RSI indicating potential overbought conditions on shorter timeframes.
Outlook remains cautiously optimistic given analyst consensus, but investors face headwinds from inflation pressures on discretionary spending and ongoing underperformance versus broader market. The 'funflation' trend supporting consumer leisure spending provides potential upside, though valuation metrics remain unavailable for comprehensive assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
